The present disclosure relates to apparatuses, systems and methods for culturing cells.
The viable cell density (VCD) that can be maintained is a primary variable driving productivity and cost in bioreactor vessels. In bioreactors one limitation to achieving the highest possible VCD is the shear force that cells experience as bags are rocked faster or impeller velocities increased to accommodate elevated nutrient and gas exchange requirements due to the high density of cells in culture. Additionally, for applications where attachment dependent cells are the product, such as for production of cells for screening, cellular therapy, or regenerative medicine applications, it can be difficult to harvest the cells from the reactor.
In recent years there have been efforts to run bioreactors in a steady state, continuously perfused mode in an effort to greatly reduce production costs while maintaining consistent quality in an automated process. Although this method has been shown to be a powerful method to maintain high cell densities, there are difficulties regarding its suitability for commercial production of therapeutic proteins. One risk is unstable expression levels after a prolonged period in culture, with cells exhibiting fastest growth potential rather than those expressing the protein of interest being selected over time.
Accordingly, new cell culture apparatuses that provide for one or more of increased stability of cells of interest, ease of harvest of attachment dependent cells, or increased viable cell density would be desirable.
In accordance with various embodiments of the present disclosure, cell culture apparatuses having one or more plates, which can be stacked, are described. The plates have a major surface defining a structured surface. The structured surface defines a plurality of wells in which cells can be cultured. The wells can have dimensions on the micrometer scale and can be configured to promote formation of spheroid cell clusters. The apparatuses described herein also have a plurality of spacers to maintain the space between stacked plates. In embodiments, such spacers include posts or spaced apart rails that extend from the major surface along the length of the plate. A plurality of flow channels are formed between adjacent plates and/or rails for perfusion of cell culture media. The structured surfaces can support very high cell density cell growth, which can be enhanced by spheroid formation. Spheroid formation should also enhance cell functional stability, as spheroids can maintain differentiated cell function indicative of a more in vivo like response relative to cells grown in a monolayer. In some embodiments, the wells in which cells are cultured are non-adherent to the cells, which can facilitate harvesting of the cells. In various embodiments described herein, the apparatuses are designed to allow for passive diffusion of metabolic gases, which can allow for lower media perfusion rates and thus subject the cultured cells to less shear.
In various embodiments, this disclosure describes a cell culture apparatus. The cell culture apparatus includes one or more plates having a first major surface and an opposing second major surface. The first major surface comprises a structured surface defining a plurality of wells. Each well has an interior surface defining an upper aperture and a nadir, wherein the upper aperture of each well has a diametric dimension in a range from 200 micrometers to 500 micrometers, or a range from 100 micrometers to 2000 micrometers. The apparatus also includes a plurality of spaced apart rails (spacers) extending from the first major surface along a length of the first major surface. A plurality of flow channels are defined between adjacent rails.
In some embodiments, provided herein are methods of producing protein (e.g., a therapeutic protein, such as a therapeutic antibody or antibody fragment), comprising: a) culturing cells expressing a protein in the wells of a cell culture apparatus as described herein; and b) isolating the protein from the cells.
In some embodiments, wells (e.g., microwells) have a cross-sectional shape approximating a sine wave. In such embodiments, the bottom of the well is rounded (e.g., hemispherically round), the side walls increase in diameter from the bottom of the well to the top and the boundary between wells is rounded. As such the top of the wells does not terminate at a right angle. In some embodiments, a well has a diameter D at the half-way point (also termed Dhalf-way) between the bottom and top, a diameter Dtop at the top of the well and a height H from bottom to top of the well. In these embodiments, Dtop is greater than D. Additional embodiments are shown in
Additional features and advantages of the subject matter of the present disclosure will be set forth in the detailed description which follows, and in part will be readily apparent to those skilled in the art from that description or recognized by practicing the subject matter of the present disclosure as described herein, including the detailed description which follows, the claims, as well as the appended drawings.
It is to be understood that both the foregoing general description and the following detailed description present embodiments of the subject matter of the present disclosure, and are intended to provide an overview or framework for understanding the nature and character of the subject matter of the present disclosure as it is claimed. The accompanying drawings are included to provide a further understanding of the subject matter of the present disclosure, and are incorporated into and constitute a part of this specification. The drawings illustrate various embodiments of the subject matter of the present disclosure and together with the description serve to explain the principles and operations of the subject matter of the present disclosure. Additionally, the drawings and descriptions are meant to be merely illustrative, and are not intended to limit the scope of the claims in any manner.
The following detailed description of specific embodiments of the present disclosure can be best understood when read in conjunction with the following drawings, where like structure is indicated with like reference numerals and in which:
Reference will now be made in greater detail to various embodiments of the subject matter of the present disclosure, some embodiments of which are illustrated in the accompanying drawings. Like numbers used in the figures refer to like components, steps and the like. However, it will be understood that the use of a number to refer to a component in a given figure is not intended to limit the component in another figure labeled with the same number. In addition, the use of different numbers to refer to components is not intended to indicate that the different numbered components cannot be the same or similar to other numbered components.
The present disclosure describes, among other things, cell culture apparatuses having a plurality of stacked plates, each having a first major surface and an opposing second major surface. The first major surface includes a structured surface defining a plurality of or an array of microwells. In embodiments, a structured surface is a substrate having an array of microwells. Each well has an interior surface defining an upper aperture and a nadir, wherein the upper aperture of each well has a diametric dimension in a range from 200 micrometers to 500 micrometers, or in a range from 100 micrometers to 2000 micrometers. The apparatus also includes a plurality of spacers to maintain a gap between stacked plates. The spacers can include plural spaced apart rails extending from the first major surface along a length of the first major surface. A plurality of flow channels are defined between adjacent rails.
In some embodiments, the wells can be configured such that cells cultured in the wells form spheroids. For example, interior surfaces of the well can be non-adherent to cells to cause the cells in the wells to associate with each other and form spheres. The spheroids can expand to size limits imposed by the geometry of the wells. In some embodiments, the wells can be coated with an ultra-low binding material to make the wells non-adherent to cells.
The formation of three-dimensional (3D) cell agglomerates such as spheroids, as opposed to two-dimensional cell culture in which the cells form a monolayer on a surface, can increase the density of cells grown in a cell culture apparatus. Increased cell density can lead to an increased metabolic burden. In various embodiments described herein diffusion of metabolic gasses occurs through the plate material, rather than relying on flow of cell culture medium, are described. Such apparatuses can be better suited to meet the metabolic demands of cells cultured in high density.
Cells cultured in three dimensions, such as spheroids, can exhibit more in vivo like functionality than their counterparts cultured in two dimensions as monolayers. In two dimensional cell culture systems, cells can attach to a substrate on which they are cultured. However, when cells are grown in three dimensions, such as spheroids, the cells interact with each other rather than attaching to the substrate. Cells cultured in three dimensions more closely resemble in vivo tissue in terms of cellular communication and the development of extracellular matrices. Spheroids thus provide a superior model for cell migration, differentiation, survival, and growth and therefore provide better systems for research, diagnostics, and drug efficacy, pharmacology, and toxicity testing.
In some embodiments, the devices are configured such that cells cultured in the devices form spheroids. For example, the wells in which cells are grown can be non-adherent to cells to cause the cells in the wells to associate with each other and form spheres. The spheroids expand to size limits imposed by the geometry of the wells. In some embodiments, the wells are coated with a non-adherent material. In embodiments, the non-adherent material is an ultra-low binding material to make the wells non-adherent to cells.
Examples of non-adherent material include perfluorinated polymers, olefins, or like polymers or mixtures thereof. Other examples include agarose, non-ionic hydrogels such as polyacrylamides, polyethers such as polyethylene oxide and polyols such as polyvinyl alcohol, or like materials or mixtures thereof. In embodiments, these may be ultra low binding materials. The combination of, for example, non-adherent wells, well geometry (e.g., size and shape), and/or gravity induce cells cultured in the wells to self-assemble into spheroids. Some spheroids maintain differentiated cell function indicative of a more in vivo-like, response relative to cells grown in a monolayer. Other cells types, such as mesenchymal stromal cells, when cultured as spheroids retain their pluripotency,
In some embodiments, the systems, devices, and methods herein comprise one or more cells. In some embodiments, the cells are cryopreserved. In some embodiments, the cells are in three dimensional culture. In some such embodiments, the systems, devices, and methods comprise one or more spheroids. In some embodiments, one or more of the cells are actively dividing. In some embodiments, the systems, devices, and methods comprise culture media (e.g., comprising nutrients (e.g., proteins, peptides, amino acids), energy (e.g., carbohydrates), essential metals and minerals (e.g., calcium, magnesium, iron, phosphates, sulphates), buffering agents (e.g., phosphates, acetates), indicators for pH change (e.g., phenol red, bromo-cresol purple), selective agents (e.g., chemicals, antimicrobial agents), etc.). In some embodiments, one or more test compounds (e.g., drug) are included in the systems, devices, and methods.
A wide variety of cell types may be cultured. In some embodiments, a spheroid contains a single cell type. In some embodiments, a spheroid contains more than one cell type. In some embodiments, where more than one spheroid is grown, each spheroid is of the same type, while in other embodiments, two or more different types of spheroids are grown. Cells grown in spheroids may be natural cells or altered cells (e.g., cell comprising one or more non-natural genetic alterations). In some embodiments, the cell is a somatic cell. In some embodiments, the cell is a stem cell or progenitor cell (e.g., embryonic stem cell, induced pluripotent stem cell) in any desired state of differentiation (e.g., pluripotent, multi-potent, fate determined, immortalized, etc.). In some embodiments, the cell is a disease cell or disease model cell. For example, in some embodiments, the spheroid comprises one or more types of cancer cells or cells that can be induced into a hyper-proliferative state (e.g., transformed cells). Cells may be from or derived from any desired tissue or organ type, including but not limited to, adrenal, bladder, blood vessel, bone, bone marrow, brain, cartilage, cervical, corneal, endometrial, esophageal, gastrointestinal, immune system (e.g., T lymphocytes, B lymphocytes, leukocytes, macrophages, and dendritic cells), liver, lung, lymphatic, muscle (e.g., cardiac muscle), neural, ovarian, pancreatic (e.g., islet cells), pituitary, prostate, renal, salivary, skin, tendon, testicular, and thyroid. In some embodiments, the cells are mammalian cells (e.g., human, mice, rat, rabbit, dog, cat, cow, pig, chicken, goat, horse, etc.).
The cultured cells find use in a wide variety of research, diagnostic, drug screening and testing, therapeutic, and industrial applications.
In some embodiments, the cells are used for production of proteins or viruses. Systems, devices, and methods that culture large numbers of spheroids in parallel are particularly effective for protein production. Three-dimensional culture allows for increased cell density, and higher protein yield per square centimeter of cell growth surface area. Any desired protein or viruses for vaccine production may be grown in the cells and isolated or purified for use as desired. In some embodiments, the protein is a native protein to the cells. In some embodiments, the protein is non-native. In some embodiments, the protein is expressed recombinantly. Preferably, the protein is overexpressed using a non-native promoter. The protein may be expressed as a fusion protein. In some embodiments, a purification or detection tag is expressed as a fusion partner to a protein of interest to facilitate its purification and/or detection. In some embodiments, fusions are expressed with a cleavable linker to allow separation of the fusion partners after purification.
In some embodiments, the protein is a therapeutic protein. Such proteins include, but are not limited to, proteins and peptides that replace a protein that is deficient or abnormal (e.g., insulin), augment an existing pathway (e.g., inhibitors or agonists), provide a novel function or activity, interfere with a molecule or organism, or deliver other compounds or proteins (e.g., radionuclides, cytotoxic drugs, effector proteins, etc.). In some embodiments, the protein is an immunoglobulin such as an antibody (e.g., monoclonal antibody) of any type (e.g., humanized, bi-specific, multi-specific, etc.). Therapeutic protein categories include, but are not limited to, antibody-based drugs, Fc fusion proteins, anticoagulants, antigens, blood factor, bone morphogenetic proteins, engineered protein scaffolds, enzymes, growth factors, hormones, interferons, interleukins, and thrombolytics. Therapeutic proteins may be used to prevent or treat cancers, immune disorders, metabolic disorders, inherited genetic disorders, infections, and other diseases and conditions.
In some embodiments, the protein is a diagnostic protein. Diagnostic proteins include, but are not limited to, antibodies, affinity binding partners (e.g., receptor-binding ligands), inhibitors, antagonists, and the like. In some embodiments, the diagnostic protein is expressed with or is a detectable moiety (e.g., fluorescent moiety, luminescent moiety (e.g., luciferase), colorimetric moiety, etc.).
In some embodiments, the protein is an industrial protein. Industrial proteins include, but are not limited to, food components, industrial enzymes, agricultural proteins, analytical enzymes, etc.
In some embodiments, the cells are used for drug discovery, characterization, efficacy testing, and toxicity testing. Such testing includes, but is not limited to, pharmacological effect assessment, carcinogenicity assessment, medical imaging agent characteristic assessment, half-life assessment, radiation safety assessment, genotoxicity testing, immunotoxicity testing, reproductive and developmental testing, drug interaction assessment, dose assessment, adsorption assessment, disposition assessment, metabolism assessment, elimination studies, etc. Specific cells types may be employed for specific tests (e.g., hepatocytes for liver toxicity, renal proximal tubule epithelial cells for nephrotoxicity, vascular endothelial cells for vascular toxicity, neuronal and glial cells for neurotoxicity, cardiomyocytes for cardiotoxicity, skeletal myocytes for rhabdomyolysis, etc.). Treated cells may be assessed for any number of desired parameters including, but not limited to, membrane integrity, cellular metabolite content, mitochondrial functions, lysosomal functions, apoptosis, genetic alterations, gene expression differences, and the like.
In some embodiments, the cell culture devices are a component of a larger system. In some embodiments, the system comprises a plurality (e.g., 2, 3, 4, 5, . . . , 10, . . . , 20, . . . , 50, . . . , 100, . . . , 1000, etc.) of such cell culture devices. In some embodiments, the system comprises an incubator for maintaining the culture devices at optimal culture conditions (e.g., temperature, atmosphere, humidity, etc.). In some embodiments, the system comprises detectors for imaging or otherwise analyzing cells. Such detectors include, but are not limited to, fluorimeters, luminometers, cameras, microscopes, plate readers (e.g., PERKIN ELMER ENVISION plate reader; PERKIN ELMER VIEWLUX plate reader), cell analyzers (e.g., GE IN Cell Analyzer 2000 and 2200; THERMO/CELLOMICS CELLNSIGHT High Content Screening Platform), and confocal imaging systems (e.g., PERKIN ELMER OPERAPHENIX high throughput content screening system; GE INCELL 6000 Cell Imaging System). In some embodiments, the system comprises perfusion systems or other components for supplying, re-supplying, and circulating culture media or other components to cultured cells. In some embodiments, the system comprises robotic components (e.g., pipettes, arms, plate movers, etc.) for automating the handing, use, and/or analysis of culture devices.
Referring now to
A structured surface of a plate as described herein may define any suitable number of wells that may have any suitable size or shape. The wells define a volume based on their size and shape. In many embodiments, one or more or all of the wells are symmetric around a longitudinal axis. In some embodiments, the longitudinal axes of one or more or all of the wells are parallel with one another. The wells may be uniformly or non-uniformly spaced. In embodiments, the wells are uniformly spaced. One or more or all the wells can have the same size and shape or can have different sizes and shapes.
Referring now to
In some embodiments, the wells 115 are gas permeable through the plate 110, i.e., through the well wall. The gas permeability of the wells 115 through the plate 110 to second major surface 114 will depend in part on the material of the plate and the thickness of the plate along the well. All else being equal, the well in
In embodiments, the wells 115 have an oxygen transmission rate through the plate 110 of 2000 cc/m2/day or greater. In embodiments, the wells have a gas permeability through the plate of 3000 cc/m2/day or greater. In embodiments, the wells have a gas permeability through the plate of 5000 cc/m2/day or greater.
Plate 110 may be formed of any material having a suitable gas permeability over at least a portion of the well. Examples of suitable materials include polydimethylsiloxane (PDMS), (poly)4-methylpentene (PMP), polyethylene (PE), and polystyrene (PS). PDMS can have a high degree of gas permeability and can be achieve sufficient gas permeabilities at thicknesses up to three to four centimeters. PMP can achieve sufficient gas permeabilities at thicknesses up to about 0.03 inches. In some embodiments, PMP having a thickness in a range of about 0.001 inch to about 0.025 inches is used to form wells. PE or PS can achieve sufficient gas permeabilities at thicknesses up to 0.005 inches, such as 0.003 inches or less. Some thinner plates may not have sufficient structural integrity. To compensate for poor structural integrity, an open frame, standoffs, or the like can be used to support the plate, or a structured surface portion thereof, from the bottom.
In embodiments, where the wells 115 are not gas permeable through the plate 110, thicker or non-gas permeable materials can be used. Examples of suitable materials for forming plates or other cell culture components described herein include polystyrene, polymethylmethacrylate, polyvinyl chloride, polycarbonate, polysulfone, polystyrene copolymers, fluoropolymers, polyesters, polyamides, polystyrene butadiene copolymers, fully hydrogenated styrenic polymers, polycarbonate PDMS copolymers, and polyolefins such as polyethylene, polypropylene, polymethyl pentene, polypropylene copolymers and cyclic olefin copolymers, and the like.
Still with reference to
In some embodiments, the inner surface of the wells 115 is non-adherent to cells. The wells may be formed from non-adherent material or may be coated with non-adherent material to form a non-adherent well. Examples of non-adherent material include perfluorinated polymers, olefins, or like polymers or mixtures thereof. Other examples include agarose, non-ionic hydrogels such as polyacrylamides, polyethers such as polyethylene oxide and polyols such as polyvinyl alcohol, or like materials or mixtures thereof. The combination of, for example, non-adherent wells, well geometry, and gravity can induce cells cultured in the wells to self-assemble into spheroids. Some spheroids can maintain differentiated cell function indicative of a more in vivo like response relative to cells grown in a monolayer.
The combination of, for example, non-adherent wells, well geometry, and gravity can define a confinement volume in which growth of cells cultured in the wells is limited.
In some embodiments, one or more wells have a concave surface, such as a hemi-spherical surface, a conical surface having a rounded bottom, and the like surface geometries or a combination thereof. The well and well bottom can ultimately terminate, end, or bottom-out in a spheroid conducive rounded or curved surface, such as a dimple, a pit, and like concave frusto-conical relief surfaces, or combinations thereof. Other shapes and construction of gas-permeable spheroid-conducive wells are described in commonly-assigned U.S. patent application Ser. No. 14/087,906, which application is hereby incorporated herein by reference in its entirety to the extent that it does not conflict with the present disclosure.
In some embodiments, well bottoms are flat or come to a point. Well bottoms may have any other suitable shape or dimension.
In some embodiments, the wells 115 described herein have a diametric dimension w in a range from about 200 micrometers to about 500 micrometers, e.g., 200, 250, 300, 350, 400, 450 or 500 micrometers, including ranges between any of the foregoing. Such diametric dimensions can control the size of a spheroid grown therein such that cells at the interior of the spheroid are maintained in a healthy state. In some embodiments, the wells 115 have a depth d in a range from about 200 micrometers to about 500 micrometers, e.g., 200, 250, 300, 350, 400, 450 or 500 micrometers, including ranges between any of the foregoing. Of course, other suitable dimensions may also be employed.
In some embodiments, the structured surface defining the wells includes an array of hexagonal close-packed well structures. An image of an embodiment of a first major surface 112 having such a structured surface is shown in
A structured surface as described herein can be formed in any suitable matter. For example, a plate or film can be molded or embossed to form the structured surface. In a further example, a heated reform tool may be applied to a molded plate. Or, a structured surface may be formed by injection molding.
A plate having a structured surface as described above may be incorporated into a cell culture apparatus. The plates may be stacked to form a cell culture apparatus. In embodiments, the stacked plates are separated by rails, with flow channels formed above a structured surface between adjacent rails.
Referring now to
Referring now to
Referring now to
For example and with reference to
The inlet port and the outlet port can be coupled to tubing, which can be coupled to a pump for delivery of cell culture media to the flow channels of the cell culture apparatus.
Final assembly of a cell culture apparatus described herein can be performed in any suitable manner. For example, units can be welded, bonded, adhered or otherwise joined together. Manifolds, reducers or expanders can be welded, bonded, adhered or otherwise joined to assembled units. By way of example, the units can be inserted into a sleeve onto which inlet and outlet manifolds are joined; stacked and manifolded units could be assembled and overmolded; bags can be heat-shrunk to form a tight fit around the stacked units; units are stacked and packed into a formed chamber or formed bag; and the like.
Referring now to
In embodiments where the inner surfaces of the wells of the structured surface of the plates are non-adherent to cells, the flow rate of cell culture media through the flow channels of the apparatus 600 can be increased to dislodge the cultured cells, which can be spheroids, from the wells to be carried with the flow of cell culture medium to cell collection cartridge. Lower flow rates can be used to grow and maintain cells within the wells. It will be understood that the shape and dimensions of the wells can be modified to alter flow rates for maintaining the cells in the wells or to dislodge the cells from the wells.
By way of example and with reference to
In some embodiments, gas flow channels can be formed in the rails that coextend with the plates. In such embodiments the rails may be formed from gas permeable materials having sufficient thicknesses to allow metabolic gas exchange from a flow channel adjacent to the rail. Examples of suitable gas permeable materials and thicknesses are described above. In some embodiments, the rails are formed from PDMS, which is relatively gas permeable. By way of example, the rails can be formed from extruded PDMS that has air channel running therethrough. PDMS can be either thermoset or thermoplastic PDMS, such as Geniomer 145 from Wacker which can have higher gas exchange rates than thermoset PDMS. PDMS, however, is well known to bind small molecules, which can be undesirable for cell culture. This could be avoided with multilayer extrusion, overmolding, coatings or other treatments to create barriers to absorption which can also act as a non-cell adhesive layer. The air channels within the rails can run the length or height of the rails. Multiple air channels can be formed in the rails
For example and with reference to
Referring now to
Regardless of the orientation of the air channels (e.g., along the length of the rails as depicted in
For example and with reference to
Referring now to
Referring now to
Additional embodiments and geometries are shown in
In some embodiments, well geometries comprise capillary structures (including, for example, a mouth, ridge fissure, rounded or parabolic top opening, etc.) in the well walls to facilitate the escape of air upon introduction of liquid into the well.
Both the relative and absolute dimensions of the wells may be selected for the desired culturing conditions. For spheroid growth, the diameter D is preferably one to three times the desired diameter of the 3D cellular aggregate to be cultured in the well. The height H is preferably 0.7 to 1.3 times D. The diameter Dtop is preferably 1.5 to 2.5 times D. D is preferably 100 micrometers (μm) to about 2000 micrometers (e.g., 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, or 2000 micrometers, including ranges between any two of the foregoing values (e.g., 200-1000 μm, 200-750 μm, 300-750 μm, 400-600 μm, etc.)). However, alternative relative or absolute dimensions may be employed. For example, D may be from 1 to 10 times (e.g., 2, 3, 4, 5, 6, 7, 8, 9) the desired diameter of the cellular aggregate or any value or range therein between (e.g., 1, 1 to 1.5, 1 to 2, 2, 1 to 2.5, 1 to 3, 2 to 3, 1 to 5, 3 to 5, 2 to 7, etc.). D may be from 100 μm to 10,000 μm or any value (e.g., 100, 200, 500, 1000, 2000, 5000) or range therein between (e.g., 100-2000, 200-1000, 300-700, 400-600, 500, etc.). H may be from 0.5 to 10 times D (e.g., 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 or any values or ranges therein between). Dtop may be from 1.1 to 5 times D (e.g., 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5 or any values or ranges therein between).
In certain embodiments, the gas permeable cell culture apparatus (e.g., spheroid perfusion bioreactor) of this disclosure permits continuous media replenishment and gas exchange for all of the spheroids on each surface in each culture compartment. In general, media replenishment and gas exchange will also be equivalent, or approximately equivalent, for all the spheroids in each culture compartment. Employing spheroid forming geometry in the wells/compartments, allows the cells added to these bioreactors to form spheroids that are all approximately the same size. Due to the gas permeability of the culture compartments an oxygenator that is typically required for bioreactors will not be required for this system to function optimally.
In certain embodiments, the gas permeable cell culture apparatus allows growing large quantities of cells in a small footprint. For example, a 400 micrometer diameter spheroid may contain an average of 30,000 cells in 3D. In a 2D surface of 400 micrometers in diameter, ˜305 cells can attach. So roughly 100 times more cells can be grown in the same unit area in 3D as can be grown in 2D. Growing this many cells in a compact footprint generally requires more nutrients and makes more waste products that need to be removed. The perfusion systems disclosed herein provide such a solution without requiring constant intervention. Moreover, the quality of the cells growing in 3D is generally higher since they function more similarly to cells in vivo.
In certain embodiments, bioreactor chambers/wells can be molded, or thermoformed from gas permeable materials, or constructed from a combination of gas permeable and non-gas permeable materials. Structural support can come in many forms, including, for example, bosses and columns. The chambers/wells may receive fresh medium in parallel through a manifold that distributes equally to all chambers, or the chambers may be fed in series, with the flow reversing from one chamber to the next.
In general, the gas exchange requirements for the cells in the vessel dictate the perfusion rate and by allowing for respiration requirements to be met via gas permeable materials of construction it allows the perfusion rate to be significantly reduced. This allows for reduced shear flow over the spheroids, which makes it easier to retain spheroids within spheroid formation/retention features in the substrates.
In embodiments where the wells are non-adherent to cells, cells cultured in the apparatuses described herein may be harvested by inverting the apparatus to allow gravity to displace the cells from the wells. Alternatively, flow rates of fluid through media flow channels can be increased to dislodge cells from wells as described above.
All scientific and technical terms used herein have meanings commonly used in the art unless otherwise specified. The definitions provided herein are to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.
As used herein, singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a “structured surface” includes examples having two or more such “structured surfaces” unless the context clearly indicates otherwise.
As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. The term “and/or” means one or all of the listed elements or a combination of any two or more of the listed elements.
As used herein, “have”, “has”, “having”, “include”, “includes”, “including”, “comprise”, “comprises”, “comprising” or the like are used in their open ended inclusive sense, and generally mean “include, but not limited to”, “includes, but not limited to”, or “including, but not limited to”.
“Optional” or “optionally” means that the subsequently described event, circumstance, or component, can or cannot occur, and that the description includes instances where the event, circumstance, or component, occurs and instances where it does not.
The words “preferred” and “preferably” refer to embodiments of the disclosure that may afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the inventive technology.
Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, examples include from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.). Where a range of values is “greater than”, “less than”, etc. a particular value, that value is included within the range.
Any direction referred to herein, such as “top,” “bottom,” “left,” “right,” “upper,” “lower,” “above,” below,” and other directions and orientations are described herein for clarity in reference to the figures and are not to be limiting of an actual device or system or use of the device or system. Many of the devices, articles or systems described herein may be used in a number of directions and orientations. Directional descriptors used herein with regard to cell culture apparatuses often refer to directions when the apparatus is oriented for purposes of culturing cells in the apparatus.
Unless otherwise expressly stated, it is in no way intended that any method set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not actually recite an order to be followed by its steps or it is not otherwise specifically stated in the claims or descriptions that the steps are to be limited to a specific order, it is no way intended that any particular order be inferred. Any recited single or multiple feature or aspect in any one claim can be combined or permuted with any other recited feature or aspect in any other claim or claims.
It is also noted that recitations herein refer to a component being “configured” or “adapted to” function in a particular way. In this respect, such a component is “configured” or “adapted to” embody a particular property, or function in a particular manner, where such recitations are structural recitations as opposed to recitations of intended use. More specifically, the references herein to the manner in which a component is “configured” or “adapted to” denotes an existing physical condition of the component and, as such, is to be taken as a definite recitation of the structural characteristics of the component.
While various features, elements or steps of particular embodiments may be disclosed using the transitional phrase “comprising,” it is to be understood that alternative embodiments, including those that may be described using the transitional phrases “consisting” or “consisting essentially of,” are implied. Thus, for example, implied alternative embodiments to a cell culture apparatus comprising a plate defining a structured surface, one or more rails, a top and one or more manifolds include embodiments where a cell culture apparatus consists of a plate defining a structured surface, one or more rails, a top and one or more manifolds and embodiments where a cell culture apparatus consists essentially of a plate defining a structured surface, one or more rails, a top and one or more manifolds.
It will be apparent to those skilled in the art that various modifications and variations can be made to the present inventive technology without departing from the spirit and scope of the disclosure. Since modifications, combinations, sub-combinations and variations of the disclosed embodiments incorporating the spirit and substance of the inventive technology may occur to persons skilled in the art, the inventive technology should be construed to include everything within the scope of the appended claims and their equivalents.
This is a continuation application of U.S. patent application Ser. No. 15/498,062 filed on Apr. 26, 2017, which claims the benefit of priority to International Patent Application Serial No. PCT/US15/58032 filed on Oct. 29, 2015, which claims the benefit of priority to U.S. Provisional Application Ser. No. 62/072,039, filed on Oct. 29, 2014, the contents of which are relied upon and incorporated herein by reference in their entirety, and the benefit of priority under 35 U.S.C. § 120 is hereby claimed.
Number | Name | Date | Kind |
---|---|---|---|
2947116 | Earle et al. | Aug 1960 | A |
3630849 | Land et al. | Dec 1971 | A |
4382685 | Pearson | May 1983 | A |
4670396 | Bear et al. | Jun 1987 | A |
4927764 | Lyman et al. | May 1990 | A |
4980293 | Jeffs | Dec 1990 | A |
5047347 | Cline | Sep 1991 | A |
5151366 | Serkes et al. | Sep 1992 | A |
5171994 | Bahraman | Dec 1992 | A |
5171995 | Gast et al. | Dec 1992 | A |
5240854 | Berry | Aug 1993 | A |
5272084 | O'Connell et al. | Dec 1993 | A |
5374557 | Verma | Dec 1994 | A |
5398837 | Degrassi | Mar 1995 | A |
5487872 | Hafeman et al. | Jan 1996 | A |
5554536 | Rising | Sep 1996 | A |
5665562 | Cook | Sep 1997 | A |
5693537 | Wilson et al. | Dec 1997 | A |
5707869 | Wolf et al. | Jan 1998 | A |
5710043 | Pay | Jan 1998 | A |
5736397 | Garcia et al. | Apr 1998 | A |
5759494 | Szlosek | Jun 1998 | A |
5772905 | Chou | Jun 1998 | A |
5783440 | Stevens | Jul 1998 | A |
5792653 | Weibezahn et al. | Aug 1998 | A |
5858309 | Mathus et al. | Jan 1999 | A |
5972694 | Mathus | Oct 1999 | A |
6030829 | Dannoux et al. | Feb 2000 | A |
6039972 | Barlow et al. | Mar 2000 | A |
6306646 | Saad et al. | Oct 2001 | B1 |
6348999 | Summersgill et al. | Feb 2002 | B1 |
6514464 | Knebel | Feb 2003 | B1 |
6521451 | Potter | Feb 2003 | B2 |
6567675 | Rosen et al. | May 2003 | B1 |
6767607 | Tanner et al. | Jul 2004 | B2 |
6811752 | Barbera-Guillem | Nov 2004 | B2 |
6908767 | Bader | Jun 2005 | B2 |
7470424 | Kataoka et al. | Dec 2008 | B2 |
7547547 | Dang et al. | Jun 2009 | B2 |
7674346 | Clements et al. | Mar 2010 | B2 |
7687262 | Cattadoris | Mar 2010 | B2 |
7691369 | Kataoka et al. | Apr 2010 | B2 |
7727759 | Ozawa et al. | Jun 2010 | B2 |
7745209 | Martin | Jun 2010 | B2 |
7745210 | Martin | Jun 2010 | B2 |
7897379 | Kenney et al. | Mar 2011 | B2 |
7919319 | Jervis et al. | Apr 2011 | B2 |
8053230 | Whittlinger | Nov 2011 | B2 |
8143053 | Yerbic | Mar 2012 | B2 |
8148152 | Kolossov et al. | Apr 2012 | B2 |
8158426 | Wilson et al. | Apr 2012 | B2 |
8158427 | Wilson et al. | Apr 2012 | B2 |
8163537 | Martin et al. | Apr 2012 | B2 |
8168432 | Wilson et al. | May 2012 | B2 |
8178345 | Bennett et al. | May 2012 | B2 |
8273572 | Martin et al. | Sep 2012 | B2 |
8318479 | Domansky et al. | Nov 2012 | B2 |
8415144 | Wilson et al. | Apr 2013 | B2 |
8470589 | Martin et al. | Jun 2013 | B2 |
D685497 | Kenney et al. | Jul 2013 | S |
8486692 | Simon | Jul 2013 | B2 |
8597597 | Deutsch et al. | Dec 2013 | B2 |
8617879 | Yu et al. | Dec 2013 | B2 |
8697443 | Wilson et al. | Apr 2014 | B2 |
8759017 | Owen et al. | Jun 2014 | B2 |
8778669 | Lacey et al. | Jul 2014 | B2 |
8846399 | Martin et al. | Sep 2014 | B2 |
8906685 | Takayama et al. | Dec 2014 | B2 |
8932544 | Mueller et al. | Jan 2015 | B2 |
9039883 | Guerrieri et al. | May 2015 | B2 |
9040293 | Gulzow et al. | May 2015 | B2 |
9045721 | Martin et al. | Jun 2015 | B2 |
9068281 | Wu et al. | Jun 2015 | B2 |
9126199 | Moritz et al. | Sep 2015 | B2 |
9169460 | Cecchi | Oct 2015 | B2 |
D748812 | Kenney et al. | Feb 2016 | S |
9260684 | Egeler et al. | Feb 2016 | B1 |
9260695 | Crowley et al. | Feb 2016 | B2 |
9493733 | Giles | Nov 2016 | B2 |
9494577 | Mcgarr et al. | Nov 2016 | B2 |
9573128 | McClelland | Feb 2017 | B1 |
9587213 | Morgan et al. | Mar 2017 | B2 |
9732317 | Wilson | Aug 2017 | B2 |
9790465 | Bennett et al. | Oct 2017 | B2 |
9845451 | Martin et al. | Dec 2017 | B2 |
9862918 | Ito | Jan 2018 | B2 |
10254274 | Miklas et al. | Apr 2019 | B2 |
20020022219 | Clements et al. | Feb 2002 | A1 |
20020172621 | Barbera-Guillem | Nov 2002 | A1 |
20030031829 | Tanner et al. | Feb 2003 | A1 |
20030104494 | Ravkin et al. | Jun 2003 | A1 |
20030183958 | Goff et al. | Oct 2003 | A1 |
20030186217 | Bader | Oct 2003 | A1 |
20030215941 | Campbell et al. | Nov 2003 | A1 |
20040091397 | Picard | May 2004 | A1 |
20040101955 | Whitley | May 2004 | A1 |
20040125266 | Miyauchi et al. | Jul 2004 | A1 |
20040216835 | Tanner et al. | Nov 2004 | A1 |
20040259242 | Malinge et al. | Dec 2004 | A1 |
20040259423 | Elbaz et al. | Dec 2004 | A1 |
20050032208 | Oh et al. | Feb 2005 | A1 |
20050047971 | Clements et al. | Mar 2005 | A1 |
20050112030 | Gaus | May 2005 | A1 |
20050116717 | Dransfield et al. | Jun 2005 | A1 |
20050147959 | Frondoza et al. | Jul 2005 | A1 |
20060110822 | Robbins et al. | May 2006 | A1 |
20060234370 | Korpinen et al. | Oct 2006 | A1 |
20060252044 | Okumura et al. | Nov 2006 | A1 |
20060292654 | Reardon | Dec 2006 | A1 |
20070178441 | Li | Aug 2007 | A1 |
20080003671 | Martin | Jan 2008 | A1 |
20080009027 | Fraker et al. | Jan 2008 | A1 |
20080118974 | Martin et al. | May 2008 | A1 |
20080206857 | Kenney et al. | Aug 2008 | A1 |
20080299649 | Martin et al. | Dec 2008 | A1 |
20080300278 | Torrens Jover et al. | Dec 2008 | A1 |
20090017540 | Nishio et al. | Jan 2009 | A1 |
20090018033 | Morgan et al. | Jan 2009 | A1 |
20090029462 | Beardsley et al. | Jan 2009 | A1 |
20090037293 | Unger et al. | Feb 2009 | A1 |
20090170190 | Nishi et al. | Jul 2009 | A1 |
20090191620 | Martin et al. | Jul 2009 | A1 |
20090288963 | Guerrieri et al. | Nov 2009 | A1 |
20090298164 | Cattadoris | Dec 2009 | A1 |
20090298166 | Fang et al. | Dec 2009 | A1 |
20100055774 | Wilson | Mar 2010 | A1 |
20100068793 | Ungrin et al. | Mar 2010 | A1 |
20100093075 | Muller | Apr 2010 | A1 |
20100112014 | Gilbert et al. | May 2010 | A1 |
20100112684 | Lee et al. | May 2010 | A1 |
20100119418 | Clements et al. | May 2010 | A1 |
20100170790 | Takahashi et al. | Jul 2010 | A1 |
20100190197 | Martin et al. | Jul 2010 | A1 |
20100197013 | Kamp et al. | Aug 2010 | A1 |
20100247386 | Deutsch et al. | Sep 2010 | A1 |
20100273258 | Lannutti et al. | Oct 2010 | A1 |
20100297600 | Cecchi | Nov 2010 | A1 |
20110086375 | Ungrin et al. | Apr 2011 | A1 |
20110097790 | Yerbic | Apr 2011 | A1 |
20110129923 | Wilson et al. | Jun 2011 | A1 |
20110229961 | Higashi et al. | Sep 2011 | A1 |
20120064627 | Khine et al. | Mar 2012 | A1 |
20120129208 | Khine | May 2012 | A1 |
20120129257 | Yu | May 2012 | A1 |
20120219572 | Prockop et al. | Aug 2012 | A1 |
20130122539 | Li et al. | May 2013 | A1 |
20130122580 | Tsukada | May 2013 | A1 |
20130143254 | Thomas et al. | Jun 2013 | A1 |
20130164848 | Munaka et al. | Jun 2013 | A1 |
20130203159 | Itoh et al. | Aug 2013 | A1 |
20130344598 | Nistor | Dec 2013 | A1 |
20140004086 | Peak | Jan 2014 | A1 |
20140027784 | Wada et al. | Jan 2014 | A1 |
20140099717 | Fraker et al. | Apr 2014 | A1 |
20140106394 | Ko et al. | Apr 2014 | A1 |
20140106452 | Vukasinovic | Apr 2014 | A1 |
20140120573 | Tavana et al. | May 2014 | A1 |
20140178992 | Nakashima et al. | Jun 2014 | A1 |
20140221225 | Danen et al. | Aug 2014 | A1 |
20140227784 | Ejiri | Aug 2014 | A1 |
20140315296 | Wilson | Oct 2014 | A1 |
20140322806 | Bennett et al. | Oct 2014 | A1 |
20150004686 | Goral et al. | Jan 2015 | A1 |
20150064738 | Tsukada et al. | Mar 2015 | A1 |
20150072405 | Ito | Mar 2015 | A1 |
20150184119 | Tsukada et al. | Jul 2015 | A1 |
20150247112 | Orr et al. | Sep 2015 | A1 |
20160003796 | Kranbuehl | Jan 2016 | A1 |
20160017267 | Hansen et al. | Jan 2016 | A1 |
20160040120 | Gottwald et al. | Feb 2016 | A1 |
20160137962 | Ejiri et al. | May 2016 | A1 |
20160194588 | Guenat et al. | Jul 2016 | A1 |
20160216250 | Ritter et al. | Jul 2016 | A1 |
20170067019 | Ho | Mar 2017 | A1 |
20170073625 | Kasuto et al. | Mar 2017 | A1 |
20170226455 | Fang et al. | Aug 2017 | A1 |
20170283757 | Carter et al. | Oct 2017 | A1 |
20170306281 | Martin et al. | Oct 2017 | A1 |
20170342363 | Fang et al. | Nov 2017 | A1 |
20180201888 | Miwa et al. | Jul 2018 | A1 |
20200239854 | Ayano et al. | Jul 2020 | A1 |
Number | Date | Country |
---|---|---|
2004256209 | Jan 2005 | AU |
2558946 | Jan 2005 | CA |
2679011 | Sep 2008 | CA |
2848875 | Mar 2013 | CA |
2186755 | Jan 1995 | CN |
1234112 | Nov 1999 | CN |
1875093 | Dec 2006 | CN |
101978041 | Feb 2011 | CN |
102105578 | Jun 2011 | CN |
102257123 | Nov 2011 | CN |
102449135 | May 2012 | CN |
202450098 | Sep 2012 | CN |
202849407 | Apr 2013 | CN |
103080294 | May 2013 | CN |
103119151 | May 2013 | CN |
203513696 | Apr 2014 | CN |
103814125 | May 2014 | CN |
204608026 | Sep 2015 | CN |
204702760 | Oct 2015 | CN |
204714819 | Oct 2015 | CN |
204752742 | Nov 2015 | CN |
204803327 | Nov 2015 | CN |
205170866 | Apr 2016 | CN |
205669029 | Nov 2016 | CN |
205839030 | Dec 2016 | CN |
205990396 | Mar 2017 | CN |
8309876 | Dec 1983 | DE |
10019862 | Nov 2001 | DE |
202006017853 | Jan 2007 | DE |
102009005526 | Jul 2010 | DE |
102014017728 | Jun 2016 | DE |
307048 | Mar 1989 | EP |
0605527 | Jul 1994 | EP |
0681846 | Nov 1995 | EP |
0800571 | Oct 1997 | EP |
965633 | Dec 1999 | EP |
1181349 | Feb 2002 | EP |
1988152 | Nov 2008 | EP |
2032262 | Mar 2009 | EP |
2617807 | Jul 2013 | EP |
2653531 | Oct 2013 | EP |
2759592 | Jul 2014 | EP |
2896684 | Jul 2015 | EP |
3296018 | Mar 2018 | EP |
3351615 | Jul 2018 | EP |
3372666 | Sep 2018 | EP |
03-139350 | Jun 1991 | JP |
06-038734 | Feb 1994 | JP |
09-234811 | Sep 1997 | JP |
10210866 | Aug 1998 | JP |
2001-106749 | Apr 2001 | JP |
2003135056 | May 2003 | JP |
2003180335 | Jul 2003 | JP |
2004129558 | Apr 2004 | JP |
2006-121991 | May 2006 | JP |
2006-191809 | Jul 2006 | JP |
2007-510429 | Apr 2007 | JP |
2009-017810 | Jan 2009 | JP |
2009-183288 | Aug 2009 | JP |
2009-542230 | Dec 2009 | JP |
2010088347 | Apr 2010 | JP |
2010104327 | May 2010 | JP |
2010-518879 | Jun 2010 | JP |
2011-509686 | Mar 2011 | JP |
2011-521642 | Jul 2011 | JP |
2011-528226 | Nov 2011 | JP |
2012249547 | Dec 2012 | JP |
2013055911 | Mar 2013 | JP |
2015012827 | Jan 2015 | JP |
2015-029431 | Feb 2015 | JP |
2015073520 | Apr 2015 | JP |
5845185 | Jan 2016 | JP |
2016-136920 | Aug 2016 | JP |
2016136921 | Aug 2016 | JP |
2017-532970 | Nov 2017 | JP |
2018-108032 | Jul 2018 | JP |
10-2014-0125662 | Oct 2014 | KR |
9307258 | Apr 1993 | WO |
9621851 | Jul 1996 | WO |
9815355 | Apr 1998 | WO |
2004044120 | May 2004 | WO |
2004094060 | Nov 2004 | WO |
2007015770 | Feb 2007 | WO |
2008006104 | Jan 2008 | WO |
2008008149 | Jan 2008 | WO |
2008106771 | Sep 2008 | WO |
2008118500 | Oct 2008 | WO |
2008140295 | Nov 2008 | WO |
2008149039 | Dec 2008 | WO |
2009148509 | Dec 2009 | WO |
2010008566 | Jan 2010 | WO |
2010042072 | Apr 2010 | WO |
2010069589 | Jun 2010 | WO |
2012036011 | Mar 2012 | WO |
2012170232 | Dec 2012 | WO |
2013042360 | Mar 2013 | WO |
2013108293 | Jul 2013 | WO |
2013116449 | Aug 2013 | WO |
2014042162 | Mar 2014 | WO |
2014072432 | May 2014 | WO |
2014140181 | Sep 2014 | WO |
2014165273 | Oct 2014 | WO |
2014179196 | Nov 2014 | WO |
2015033507 | Mar 2015 | WO |
2015061907 | May 2015 | WO |
2016064757 | Apr 2016 | WO |
2016069892 | May 2016 | WO |
2016069917 | May 2016 | WO |
2016069930 | May 2016 | WO |
2017047735 | Mar 2017 | WO |
2017077163 | May 2017 | WO |
2017142410 | Aug 2017 | WO |
2018200893 | Nov 2018 | WO |
2019014621 | Jan 2019 | WO |
2019014627 | Jan 2019 | WO |
2019014635 | Jan 2019 | WO |
2019014636 | Jan 2019 | WO |
2019178039 | Sep 2019 | WO |
Entry |
---|
Achilli; “Advances in the Formation, Use and Understanding of Muli-Cellular Spheroids” , Expert Opin. Biol. Ther. (2012) 12 (10) 1347-1360. |
Alepee et al. “State of the art 3D cultures (organs-on-a-chip) in safety testing and pathophysiology” Trnasatlantic Think Tank for Toxicology, t4 Workshop Report, Altex 31 4/14, pp. 441-477, retrieved from: http://dx.doi.org/10.14573/altex1406111 (Jul. 14, 2014. |
G-Plate: Accelerate your cell cultures to the next dimension, An original cell culture model allowing for inland shaped 3D cell aggregates “1 page, retrieved Sep. 8, 2015”. |
Anada et al; “An Oxygen-Permeable Spheroid Culture System for the Prevention of Central Hypoxia and Necrosis of Spheroids” ; Biomaterials, 33, (2012) 8430-8441. |
Bartosh et al; “Aggregation of Human Mesenchymal Stromal Cells (MSCS) Into 3D Spheroid Enhances Their Antiinflammatory Properties” ; PNAS, Aug. 3, 2010, vol. 107, No. 31 pp. 13724-13729. |
Carver et al; “Multicellular Tumor Spheroids as a Model for Assessing Delivery of Oligonucleotides in Three Dimensions” ; Molecular Therapy-Nucleic Acids (2014) 3, E153; 8 Pages. |
Chen et al. “Microfluidic array for 3-dimensional perfusion culture of human mammary epithelial cells”, Biomedical Microdevices (2011) vol. 13, issue 4. p. 753-758. |
Choi et al., “Feasibility of a simple double-layered coculture system incorporating metabolic processes of the intestine and liver tissue: application to the analysis of benzo[a]pyrene toxicity” Toxicology in Vitro, vol. 18, pp. 393-402, 2004. |
Dolznig and Walzl, “Organotypic spheroid cultures to study tumor-stroma interactions during cancer development.” Drug discovery today, V 8., No. 2-3, 2011, 113-118. |
Endo et al., Drug Deliv. and Transl. Res., 2012, vol. 2, p. 398-405. |
Engelberg and Ropella, “Essential operating principles for tumor spheroid growth.” BMC Systems Biology 2008, 2, 110. |
Friedrich et al “Experimental anti-tumor therapy in 3-D: spheroidsold hat or new challenge?” Int J Radiat Biol 2007, 83:849-871. |
Friedrich et al. “Spheroid based drug screen: considerations and practical approach.” Nature protocols, 2009, vol. 4 No. 3, 309-323. |
Frith et al. “Dynamic three-dimensional culture methods enhance mesenchymal stem cell properties and increase therapeutic potential.” Tissue engineering, 2010, 16, No. 4, 735-749. |
Fukuda et al. “Efficacy of a polyurethane foam/spheroid artificial liver using human hepatoblastoma cell line (HepG2).” Cell Transplant 2003; 12:518. |
Haycock. “3D cell culture: a review of current approaches and techniques.” Methods Mol Biol. 2011;695:1-15. |
Hirschhaeuser et al., “Mulicellular tumor spheroids: An underestimated tool is catching up again.” Journal of Biotechnology, 2010, 148, 3-15. |
Howes et al; “3-Dimensional Culture Systems for Anit-Cancer Compound Profiling and High-Throughput Screening Reveal Increases in EGFR Inhibitor-Mediated Cytotoxicity Compared to Monolayer Culture Systems”; Plos One; Sep. 2004, vol. 9, Issue 9, 11 Pages. |
Hribar et al; “Nonlinear 3D Projection Printing of Concave Hydrogel Microstructures for Long-Term Multicellular Spheroid and Embryoid Body Culture” ; Lab Chip, 2015, 15, 2412-2418. |
Hwang et al; “Microwell-Mediated Control of Embryoid Body Size Regulates Embryonic Stem Cell Fate Via Differential Expression of WNT5A and WNT11”; PNAS; Oct. 6, 2009, vol. 106, No. 40, pp. 16978-16983. |
Kelm et al. “Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types.” Biotechnol Bioeng 2003;83:17380. |
Koide et al. “Formation of multicellular spheroids composed of adult rat hepatocytes in dish with positively charged surfaces and under other nonadherent environments.” Exp Cell Res 1990;186: 22735. |
Kunz-Schughart et al “The use of 3-D cultures for high-throughput screening: the multicellular spheroid model.” J Biomol Screen 2004, 9:273-285. |
Kutsuzawa et al; “Highly Robust Protein Production by Co-Culture of Cho Spheroids Layared on Feeder Cells in Serum-Free Medium” ; Colloid Polym Sci (2014) 292; 839-848. |
Landry et al. “Spheroidal aggregate culture of rat liver cell: histotypic reorganization, biomatrix deposition, and maintenance of functional activities.” J Cell Biol 1985;101:91423. |
Lau et al., “Evaluation of a Novel in Vitro CACO-2 Hepatocyte Hybrid System for Predicting in Vivo Oral Bioavailability” Drug Metabolism and Disposition, vol. 32, No. 9, pp. 937-942, 2004. |
Liu et al. “Quasi-spherical microwells on superhydrophobic substrates for long term culture of multicellular spheroids and high throughput assays” Biomaterials and Cancer 35 (2014) pp. 6060-6068. |
Lu et al. “Galactosylated PVDF membrane promotes hepatocyte attachment and functional maintenance.” Biomaterials 2003;24:4893903. |
Markovitz-Bishitz, “A polymer microstructure array for the formation, culturing, and high throughput drug screening of breast cancer spheroids” Biomaterials and Biotechnology 31 (2010) pp. 8436-8444. |
Messner et al., Multi-cell type human liver microtissues for hepatotoxicity testing. Archives of Toxicology Nov. 11, 2012. |
Mironov et al; “Organ Printing: Tissue Spheroids as Buliding Blocks” Biomaterials, 2009; 30 (12) 2164-2174. |
Moon et al; “Optimizing Human Embryonic Stem Cells Differentiation Efficiency by Screening Size-Tunable Homogenous Embryoid Bodies” ; Biomaterials; 35 (2014) 5987-5997. |
Urich et al; “Multicellular Self-Assembled Spheroidal Model of the Blood Brain Barrier ”; Scientific Reports, 3, 1500, 8 Pages. |
Murphy et al; “3D Bioprinting of Tissues and Organs” ; Nature Biotechnology, vol. 32, No. 8, Aug. 2014, pp. 773-785. |
Otsuka et al. “Two-dimensional multiarray formation of hepatocyte spheroids on a microfabricated PEG-brush surface.” Chembiochem 2004;5:8505. |
Peshwa et al. “Mechanistics of formation and ultrastructural evaluation of hepatocyte spheroids.” In Vitro Cell Dev Biol Anim 1996;32:197203. |
Rezende et al; Scalable Biofabrication of Tissue Spheroids for Organ Printing; Sciverse Science Direct, Porcedia Cirp 5, (2013) 276-281. |
Sa et al. “Round-bottomed Honeycomb Microwells: Embryoid body shape correlates with stem cell fate” Journal of Developmental Biology and Tissue Engineering vol. 4(2), pp. 12-22, May 2012. |
Sakai et al. “Large-scale preparation and function of porcine hepatocyte spheroids.” Int J Artif Organs 1996;19:294301. |
Sakai et al; “Detachably Assembled Microfluidic Device for Perfusion Culture and Post-Culture Analysis of Spheroid Array” ; Biotechnol. J. 2014, 9, 971-979. |
Sakai et al; “Technique for the Control of Spheroid Diameter Using Microfabricated Chips” ; Sciencedirect, Acta Biomaterials 3 (2007) 1033-1040. |
Sart et al. “Three-dimensional aggregates of mesenchymal stem cells: cellular mechanisms, biological properties and applications.” Tissue engineering, 2013, Part B, 00, No. 00, 1-16. |
Seldon et al; “Evaluation of Encapsulated Liver Cell Spheroids in a Fluidised-Bed Bioartificial Liver for Treatment of Ischaemic Acute Liver Failure in Pigs in the Translational Setting” ; Plos One; Dec. 2013, vol. 8, Issue 12, 12 Pages. |
Takezawa et al. “Morphological and immunocytochemical characterization of a heterospheroid composed of fibroblasts and hepatocytes.” J Cell Sci 1992;101:495501. |
Tobe et al. “Receptor-mediated formation of multilayer aggregation of primary rat hepatocytes on lactose-substituted polystyrene.” Biochem Biophys Res Commun 1992;184:22530. |
Tong et al. “Long-term culture of adult rat hepatocyte spheroids.” Exp Cell Res 1992;200:32632. |
Truckemller, et al., Thermoforming of Film-Based Biomedical Microdevices, Adv. Mater. 2011, 23, pp. 1311-1329. |
Tung et al. “High-throughput 3D spheroid culture and drug testing using 384 hanging drop array.” Analyst, 2011, 136, 473-478. |
Uchida et al: “An Injectable Spheroid System With Genetic Modification for Cell Transplantation Therapy” ; Biomaterials, 35 (2014) 2499-2506. |
Weegman et al; “Nutrient Regulation by Continuous Feeding Removes Limitation on Cell Yeild in the Large-Scale Expansion of Mamalian Cell Spheroids”; Plos One; Oct. 2013, vol. 8, Issue 10, 10 Pages. |
Xu et al. “Characterization of some cytotoxic endpoints using rat liver and HepG2 spheroids as in vitro models and their application in hepatotoxicity studies. I. Glucose metabolism and enzyme release as cytotoxic markers.” Toxicol Appl Pharmacol 2003:189:10011. |
Yamada et al. “Efficient induction of hepatocyte spheroids in a suspension culture using a water-soluble synthetic polymer as an artificial matrix.” J Biochem 1998;123: 101723. |
Japanese Patent Application No. 2017523433; Machine Translation of the Office Action dated Sep. 4, 2019; Japan Patent Office; 7 Pgs. |
Stemcell Technologies, Reproducible and Uniform Embryoid Bodies Using AggreWell Plates, StemCell Technologies, Version 3.0.0, Mar. 2011, Catalog #29146, pp. 1-28. |
Chinese Search Report; 201580071454.0; dated Sep. 19, 2019, 2 Pages; Chinese Patent Office. |
Chinese Supplementary Search Report; 201580071454.0; dated Aug. 24, 2020; 2 Pages; Chinese Patent Office. |
Labusca, “Scaffold free 3D culture of mesenchymal stem cells; implications for regenerative medicine”, J Transplant Stem Cel Biol 2015 2(1): 8. |
Lovett et al. “Vascularization Strategies for Tissue Engineering” Tissue Engineering Part B, 2009, vol. 15, No. 3, pp. 353-370. |
Aline; “We Engineer Microfluidic Products”; 7 Pages; (2020) https://alineinc.com/. |
Bioivt Elevating Science ®; 6 Pages; (2020); http://www.hepregen.com/. |
Cheng et al, “Microrna-34a Targets Forkhead Box J2 To Modulate Differentiation of Endothelial Progenitor Cells in Response to Shear Stress”, J Mol Cell Cardiol. 74 (2014) 4-12. |
CN-Bio, “Transforming Drug Discovery and the Lives of Patients”; 5 Pages; (2020) http://cn-bio.com/. |
Colazzo et al, “Shear Stress and VEGF Enhance Endothelial Differentiation of Human Adipose-Derived Stem Cells”, Growth Factors, 2014, 32(5):139-149. |
Corning® HTS Transwell®-96 Tissue Culture Systems, Permeable Supports for High Throughput Screening Applications; 2 Pages (2004). |
Tissue Dynamics; “Disruptive Drug Development ”; 3 Pages; (Downloaded Mar. 9, 2020); https://www.tissuedynamics.com/. |
Domansky et al, “Perfused Multiwell Plate for 3D Liver Tissue Engineering”, Lab Chip, 2010, 10:51-58. |
Emulate; 6 Pages; (2019) https://emulatebio.com/. |
Tissuse; “Emulating Human Biology, Pioneering Human-on-a-Chip Developments”; 1 Page; (Downloaded Mar. 9, 2020) https://www.tissuse.com/en/. |
GeoChem Incorporated, Product Line; https://www.geocheminc.com, 4 Pages; (2020). |
Hμrel ® Corporation, Bioanalytic Tools Company; 2 Pages; (2013); http://hurelcorp.com/. |
Jeon et al, “Combined Effects of Flow-Induced Shear Stress and Micropatterned Surface Morphology on Neuronal Differentiation of Human Mesenchymal Stem Cells” J Biosci Bioeng, 2014, 117(2):242-247. |
Jiang et al, “Shear Enhances Thrombopoiesis and Formation of Microparticles That Induce Megakaryocytic Differentiation of Stem Cells”, Blood, Sep. 25, 2014; 124(13):2094-2103. |
Kim et al, “Shear Stress Induced by an Interstitial Level of Slow Flow Increases the Osteogenic Differentiation of Mesenchymal Stem Cells Through TAZ Activation” PLoS ONE, Mar. 21, 2014; 9(3), e92427, 9 pages. |
Liquid Surge Control, LLC; “The Latest in Drop-In Baffle Technology”; 2 Pages; (2019). |
Elveflow; “Microfluidics Innovation Center”; 6 Pages; (Downloaded Mar. 9, 2020); https://www.elveflow.com/. |
Nortis; “Bridging the Gap Between in Vitro and in Vivo Research”; 16 Pages; (2015); https://www.nortisbio.com/. |
Mimetas the Organ-on-A-Chip Company; “Organ-on-A-Chip Models for Science and Pharma”; 4 Pages; (Downloaded Mar. 9, 2020); https://mimetas.com/. |
Organovo; “Pioneering Bioprinted Tissues to Treat Disease ”; 2 Pages; (Downloaded Mar. 9, 2020) http://organovo.com/. |
Satoh et al, “A Pneumatic Pressure-Driven Multi-Throughput Microfluidic Circulation Culture System” Lab Chip, 2016, 16, 2339-2348. |
Tara; “Innovating Predictive Cardiac Physiology”; 4 Pages; (2019) http://tarabiosystems.com/. |
The Lab Depot® Products for Discovery Lab Supplies; Shake Flasks, 3 and 4 Baffles Product Information; 5 Pages (2019). |
Wikipedia; “Antiroll Tanks”; 3 Pages; Page Last Edited May 23, 2019. |
Wrighton et al, “Forces of Change: Mechanics Underlying Formation of Functional 3D Drgan Buds” Cell Stem Cell, May 7, 2015; 16(5):453-454. |
Axosim, Nerve-on-a-Chip Mini-Brain About Team; 6 Pages; (Downloaded Mar. 9, 2020); http://axosim.com/. |
Corning Life Sciences Product Portfolio; 5 Pages Saved Mar. 6, 2020. |
“Laboratory Flasks Selection Guide: Types, Features, Applications”, Engineering360, <https://www.globalspec.com/learnmore/labware_scientific_instruments/labware_consumables/laboratory_flasks#:˜:text=Laboratory%20flasks%20are%20lab%20vessels,the%20opening%20at%20the%20neck.> accessed Apr. 8, 2022 (Year: 2022). |
Achilli et al., “Advances In The Formation, Use And Understanding Of Multi-cellular Spheroids”, Expert Opinion On Biological Therapy, vol. 12, No. 10, Jul. 2012, pp. 1347-1360. |
Brandrup et al., “Polymer Handbook”, Fourth Edition, Wiley-Interscience Publication, , Permeability and diffusion data, 1999, 9 pages (Contributors; Preface). |
Endo et al., “Gene transfection to spheroid culture system on micropattemed culture plate by polyplex nanomicelle: a novel platform of genetically-modified cell transplantation”, Drug Deliv. and Transl. Res., 2012, vol. 2, p. 398-405. |
Hsiao et al., “Effects of 3D Microwell Culture on Initial Fate Specification in Human Embryonic Stem Cells”, Published in final edited form as AIChE J. vol. 60 No.4, Apr. 2014, pp. 1225-1235. |
International Search Report and Written Opinion of the International Searching Authority; PCT/US2021/059622; dated May 23, 2022, 11 pages; European Patent Office. |
Junji Fukuda et al., “Hepatocyte Spheroid Arrays Inside Microwells Connected With Microchannels”, BIOMICROFLUIDICS 5, 2011, pp. 10. |
Lonza Inc., “SeaPrep Agarose: An Ultralow Gelling, Soft Agarose”, Available Online at <http://www.lonzabio.jp/catalog/pdf/pd/PD031.pdf>, 2007, pp. 1-4. |
Martin et al., “Agarose And Methylcellulose Hydrogel Blends For Nerve Regeneration Applications”, J. Neural Eng., vol. 5, 2008, pp. 221-231. |
McMillan, “Shear stress in microfluidic devices” Darwin Microfludics internet article (Year: 2017). |
Singapore Patent Application No. 11201703500X, Office Action dated Mar. 9, 2021; 8 pages; Singapore Patent Office. |
WO-2008149039 translation (Year: 2008). |
Yang et al.,“An Agarose-Gel Based Method for Transporting Cell Lines”, Current Chemical Genomics, vol. 3, Jan. 2009, pp. 50-53. |
Zuidema et al., “Fabrication And Characterization Of Tunable Polysaccharide Hydrogel Blends For Neural Repair”, Acta Biomaterialia, vol. 7, No. 4, Apr. 2011, pp. 1634-1643. |
Number | Date | Country | |
---|---|---|---|
20200148990 A1 | May 2020 | US |
Number | Date | Country | |
---|---|---|---|
62072039 | Oct 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15498062 | Apr 2017 | US |
Child | 16569852 | US | |
Parent | PCT/US2015/058032 | Oct 2015 | US |
Child | 15498062 | US |